{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:21:37Z","timestamp":1792815697444,"version":"4.5.0"},"reference-count":28,"publisher":"Massachusetts Medical Society","issue":"4","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"DOI":"10.13039\/100019650","name":"Vir Biotechnology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019650","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2026,1,22]]},"DOI":"10.1056\/nejmoa2508827","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T23:00:09Z","timestamp":1762729209000},"page":"343-353","source":"Crossref","is-referenced-by-count":21,"title":["A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D"],"prefix":"10.1056","volume":"394","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0024-0595","authenticated-orcid":false,"given":"Tarik","family":"Asselah","sequence":"first","affiliation":[{"name":"Universit\u00e9 Paris\u2013Cit\u00e9, H\u00f4pital Beaujon, Assistance Publique\u2013H\u00f4pitaux de Paris, INSERM Unit\u00e9 Mixte de Recherche 1149, Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Chattergoon","sequence":"additional","affiliation":[{"name":"Vir Biotechnology, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Jucov","sequence":"additional","affiliation":[{"name":"Arensia Exploratory Medicine, D\u00fcsseldorf, Germany"},{"name":"Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Streinu-Cercel","sequence":"additional","affiliation":[{"name":"National Institute for Infectious Diseases Matei Bal\u015f, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan"},{"name":"CRC \u201cA. M. and A. Migliavacca\u201d Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, Infectious Diseases, and Endocrinology, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick T.","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Centre for Immunobiology and Infection, Blizard Institute, Barts and the London School of Medicine and Dentistry, London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Gane","sequence":"additional","affiliation":[{"name":"Auckland Clinical Studies, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna L.","family":"Bullard","sequence":"additional","affiliation":[{"name":"Vir Biotechnology, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Chow","sequence":"additional","affiliation":[{"name":"Vir Biotechnology, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree","family":"Santos","sequence":"additional","affiliation":[{"name":"Vir Biotechnology, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Camus","sequence":"additional","affiliation":[{"name":"Vir Biotechnology, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimeng","family":"Lu","sequence":"additional","affiliation":[{"name":"Vir Biotechnology, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Pilowa","sequence":"additional","affiliation":[{"name":"Vir Biotechnology, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carey","family":"Hwang","sequence":"additional","affiliation":[{"name":"Vir Biotechnology, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Correll","sequence":"additional","affiliation":[{"name":"Vir Biotechnology, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies, College Hospital, London"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2212151"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.05.001"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100818"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.008"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.01.014"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31214"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.02.030"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10575-0"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16006"},{"key":"e_1_3_5_11_2","unstructured":"Hepcludex. Summary of product characteristics. Cork Ireland: Gilead Sciences 2020 (https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hepcludex-epar-product-information_en.pdf)."},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2016.10.002"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213429"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100751"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.05.001"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314134"},{"key":"e_1_3_5_17_2","doi-asserted-by":"crossref","unstructured":"Aleman S Brunetto M Blank A et al. Predictors of undetectable hepatitis delta virus RNA at 48 weeks after end of treatment with bulevirtide monotherapy in the MYR301 study. Presented at the International Liver Congress: European Association for the Study of the Liver (EASL) Amsterdam May 7\u201310 2025. abstract OS-066.","DOI":"10.1136\/gutjnl-2025-BASL.184"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70008"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.07.003"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.08.016"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00237-1"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.05.023"},{"key":"e_1_3_5_23_2","unstructured":"Food and Drug Administration. Chronic hepatitis D virus infection: developing drugs for treatment. Guidance for industry. November 2019 (https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/chronic-hepatitis-d-virus-infection-developing-drugs-treatment-guidance-industry)."},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158557"},{"key":"e_1_3_5_25_2","doi-asserted-by":"crossref","unstructured":"Wedemeyer H Gane E Agarwal K et al. Treatment with siRNA JNJ-73763989 plus nucleos(t)ide analogue (NA) decreases HBsAg and HDV RNA levels in patients with chronic hepatitis D (CHD): part 1 of the REEF-D study. Presented at the International Liver Congress: European Association for the Study of the Liver (EASL) Vienna June 21\u201324 2023. abstract OS-030.","DOI":"10.1016\/S0168-8278(23)00487-7"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101400"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3003"},{"key":"e_1_3_5_28_2","unstructured":"Asselah T Streinu-Cercel A Jucov A et al. The monoclonal antibody VIR-3434 and siRNA VIR-2218 for the treatment of chronic hepatitis D virus: preliminary results from the phase 2 SOLSTICE trial. Presented at the Liver Meeting: American Association for the Study of Liver Diseases (AASLD) Boston November 10\u201314 2023. abstract 5004."},{"key":"e_1_3_5_29_2","unstructured":"Reau N Lampertico P Asselah T et al. ECLIPSE: a pivotal program evaluating once-monthly combination therapy with tobevibart and elebsiran for chronic HDV infection \u2014 rationale study design and objectives. Presented at the Liver Meeting: American Association for the Study of Liver Diseases (AASLD) Washington DC November 7\u201311 2025. abstract 2258."}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2508827","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T22:00:41Z","timestamp":1769032841000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2508827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,1,22]]}},"alternative-id":["10.1056\/NEJMoa2508827"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2508827","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]}}}